Il-17 Family Cytokines in Psoriasis: Radioactive Splendor Dual Role in Inflammation and Tissue Re Modeling

Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA, 323(19), 1945–1960. https://doi.org/10.1001/jama.2020.4006

Lubrano, E., Perrotta, F. M., & Adinolfi, A. (2021). The role of IL-17 in spondyloarthritis and psoriasis. Therapeutic Advances in Chronic Disease, 12, 2040622321999584

Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., ... & Krueger, J. G. (2016). Psoriasis. Nature Reviews Disease Primers, 2(1), 16082.

Koga, C., Kabashima, K., & Tokura, Y. (2021). Th17 and Th22 cells in skin diseases. Journal of Dermatological Science, 101(2), 106–112.

Baeten, D., Østergaard, M., Wei, J. C., Sieper, J., Järvinen, P., Tam, L. S., ... & van der Heijde, D. (2018). Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: A randomized, double-blind, placebo-controlled, phase 2 study. Lancet, 392(10162), 2385–2397.

Cheng, J. B., Sedgewick, A. J., Finnegan, A. I., Harirchian, P., Lee, J., Kwon, S., ... & Liao, W. (2019). Transcriptional programming of normal and inflamed human epidermis at single-cell resolution. Cell Reports, 28(4), 977–990.e6.

Ramesh, R., Sultana, S., & Yadav, R. N. S. (2022). Interleukin-17 family cytokines: Emerging therapeutic targets in psoriasis. International Journal of Molecular Sciences, 23(4), 1974.

Vandeghinste, N., Klattig, J., Jagerschmidt, C., Lavazais, S., Marsais, F., Haas, J. D., ... & Bertolino, P. (2018). Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis. Journal of Investigative Dermatology, 138(7), 1555–1563.

Klarquist, J., Chitrakar, A., Zhou, Z., & Hoover, A. R. (2019). IL-17C: A key epithelial cytokine in psoriasis. Immunologic Research, 67(1), 24–32.

Bissonnette, R., Nigen, S., Langley, R. G., Papp, K. A., & Lynde, C. W. (2023). Interleukin-17E (IL-25): Emerging role in chronic inflammatory skin diseases. Dermatologic Therapy, 36(1), e15310.

Kim, J., Krueger, J. G., & Herron, M. D. (2021). IL-17 and the skin barrier: Dysregulation in psoriasis. Experimental Dermatology, 30(3), 407–417.

Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2019). Immunology of psoriasis. Annual Review of Immunology, 37, 563–595.

Noda, S., Miyagawa, F., & Aiba, S. (2021). Transcriptomic signature of residual inflammation in post-treatment psoriasis. Clinical Immunology, 225, 108674.

Gisondi, P., Facheris, P., Dapavo, P., Piaserico, S., Conti, A., & Girolomoni, G. (2020). Secukinumab and ixekizumab in the treatment of moderate-to-severe plaque psoriasis: A review. Dermatologic Therapy, 33(2), e13451.

Boehncke, W. H. (2018). Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Frontiers in Immunology, 9, 579. https://doi.org/10.3389/fimmu.2018.00579

Eyerich, K., Eyerich, S., & Traidl-Hoffmann, C. (2021). Skin immune memory in inflammatory disease. Journal of Clinical Investigation, 131(1), e143067.

Luo, Q., Lin, M., Yu, H., Zhang, M., Zhang, J., & He, J. (2024). Residual IL-17–driven fibroblast activation as a mechanism of disease persistence in psoriasis. Journal of Investigative Dermatology, 144(2), 198–208.

Al-Janabi, A., Natta, F., Di Lullo, A., & Girolomoni, G. (2019). Elevated serum IL-17 levels correlate with disease severity in psoriasis. Journal of Dermatological Treatment, 30(6), 577–581. https://doi.org/10.1080/09546634.2019.1577592

Mahil, S. K., Capon, F., & Barker, J. N. (2022). Update on psoriasis pathogenesis and targeted therapies. Clinical and Experimental Dermatology, 47(3), 404–412. https://doi.org/10.1111/ced.15010

Zhao, Y., Chen, J., & Yang, Y. (2021). IL-17A and IL-17F: Dual drivers of inflammation in psoriasis. Cytokine, 141, 155446. https://doi.org/10.1016/j.cyto.2021.

Piskin, G., Tursen, U., & Dursun, R. (2023). Comparative analysis of IL-17A and IL-17F levels in chronic plaque psoriasis. Clinical and Experimental Dermatology, 48(3), 263–270. https://doi.org/10.1111/ced.15365

Liu, Y., Zhao, Q., Zhao, X., & Zhang, Z. (2022). Keratinocyte-derived IL-17C amplifies cutaneous inflammation in psoriasis. International Immunopharmacology, 107, 108626. https://doi.org/10.1016/j.intimp.2022.108626

Wang, C. Q., Jin, H., & Oyoshi, M. K. (2018). IL-17C amplifies innate immune responses in psoriatic inflammation. Journal of Investigative Dermatology, 138(2), 441–450. https://doi.org/10.1016/j.jid.2017.10.042

Murakami, M., Kubo, S., & Nakae, S. (2023). IL-17C amplifies inflammatory responses in psoriatic epidermis. Journal of Dermatology, 50(2), 189–197. https://doi.org/10.1111/1346-8138.16722

Kwok, C. Y., Chung, H. L., & Wong, P. T. (2019). IL-17C modulates keratinocyte inflammation via autocrine signaling. International Journal of Molecular Sciences, 20(12), 2921. https://doi.org/10.3390/ijms2012292

Chen, R. Y., Yang, Y. T., Lin, Y. C., & Huang, Y. F. (2023). IL-25 upregulation exacerbates psoriasiform inflammation via TSLP-dependent pathways. Scientific Reports, 13(1), 3514. https://doi.org/10.1038/s41598-023-30514-9

Vasudevan, B., Verma, R., & Mohanty, P. (2020). Elevated IL-25 expression in chronic psoriasis and correlation with disease severity. Indian Journal of Dermatology, 65(5), 379–384. https://doi.org/10.4103/ijd.IJD_676_20

Lai, Y. H., Chen, Y. C., & Chen, Y. J. (2022). IL-25 promotes psoriasiform inflammation via eosinophil-independent mechanisms. Experimental Dermatology, 31(11), 1732–1739. https://doi.org/10.1111/exd.14619

Fang, Y., Xu, M., Zhang, J., & Xu, L. (2020). Circulating IL-17F as a biomarker of severe psoriasis and therapeutic resistance. BMC Immunology, 21(1), 43. https://doi.org/10.1186/s12865-020-00363-2

Ibrahim, S. M., Abdel-Rahman, A. M., & Mahmoud, F. F. (2022). Serum IL-17F levels correlate with psoriasis severity and therapeutic outcomes. International Journal of Dermatology, 61(9), 1134–1140. https://doi.org/10.1111/ijd.16253

Obeidat, D., Alzoubi, K. H., & Zihlif, M. A. (2021). IL-17C and disease severity in Middle Eastern psoriasis patients. Journal of Inflammation Research, 14, 3019–3026. https://doi.org/10.2147/JIR.S318414

Singh, T. P., Schön, M. P., & Wallbrecht, K. (2018). IL-17A and MMP-9 expression in psoriatic skin and therapeutic implications. American Journal of Pathology, 188(8), 1740–1750. https://doi.org/10.1016/j.ajpath.2018.04.009

Kumar, R., Sehgal, R., & Sharma, A. (2019). MMP-9 as a marker of inflammation and tissue destruction in chronic psoriasis. Inflammation Research, 68(3), 215–224. https://doi.org/10.1007/s00011-019-01231-4

Xu, Z., Yang, S., & Wu, J. (2024). MMP-9 modulates epidermal barrier function in psoriasis via keratinocyte desquamation. International Journal of Molecular Sciences, 25(3), 1764. https://doi.org/10.3390/ijms25031764

Baek, J. O., Kim, D. H., & Choi, Y. W. (2023). MMP-9 as a predictor of psoriatic lesion thickness and neutrophil infiltration. Journal of Dermatology, 50(1), 25–33. https://doi.org/10.1111/1346-8138.16513

Zeng, J., Zhao, Q., & Luo, Y. (2019). IL-17A–driven keratinocyte hyperproliferation via ERK1/2 pathway. Biomedicine & Pharmacotherapy, 112, 108610. https://doi.org/10.1016/j.biopha.2019.108610

Adachi, Y., Yamada, T., Watanabe, K., Tanaka, S., & Ojima, A. (2022). IL-17A induces epidermal hyperplasia via STAT3 and ERK1/2 signaling in human keratinocytes. Experimental Dermatology, 31(3), 421–429. https://doi.org/10.1111/exd.14422

Bai, Z., Li, L., Zhang, Y., & Xu, L. (2021). TRAF6–NF-κB axis mediates IL-17C–induced keratinocyte proliferation in psoriasis. Immunology Letters, 239, 15–22. https://doi.org/10.1016/j.imlet.2021.09.004

El-Khoueiry, P., Tadros, M. A., & El-Maghraby, R. (2022). Role of IL-17C/TRAF signaling in keratinocyte proliferation in psoriasis. Immunobiology, 227(1), 152136. https://doi.org/10.1016/j.imbio.2021.152136

Khalaf, M. M., El-Deeb, A. A., & Hassan, H. S. (2019). IL-17C–NF-κB pathway activation contributes to psoriasis pathogenesis. Journal of Inflammation Research, 12, 251–260. https://doi.org/10.2147/JIR.S215776

Koizumi, H., Tohyama, M., & Hashimoto, K. (2018). IL-17-induced cytokine production by keratinocytes involves MAPK and C/EBPβ signaling. Archives of Dermatological Research, 310(4), 335–343. https://doi.org/10.1007/s00403-018-1841-9

Miao, C., Xu, L., & Zhao, W. (2023). IL-17–induced CXCL8 release from keratinocytes via p38 MAPK signaling. Cytokine, 164, 156048. https://doi.org/10.1016/j.cyto.2023.156048

Tsoi, L. C., Iyer, M. K., & Stuart, P. E. (2019). Functional genomics of keratinocyte response to cytokines in psoriasis. Journal of Investigative Dermatology, 139(1), 61–73. https://doi.org/10.1016/j.jid.2018.08.030

Masuda, K., Ito, Y., & Tsuji, G. (2022). S100A9 expression correlates with neutrophil accumulation in psoriatic lesions. Journal of Cutaneous Immunology and Allergy, 5(1), 11–19. https://doi.org/10.1111/ciaa.12420

Ramirez, L. C., Nguyen, M. T., & Tsoi, L. C. (2022). Extracellular matrix remodeling genes in chronic psoriasis. Frontiers in Immunology, 13, 875134. https://doi.org/10.3389/fimmu.2022.875134

Wei, Q., Zhou, Y., & Zhang, J. (2019). Dermal remodeling and fibrotic features in psoriasis. Journal of Dermatological Science, 96(2), 102–110. https://doi.org/10.1016/j.jdermsci.2019.09.005

Dainichi, T., Kitoh, A., Otsuka, A., & Kabashima, K. (2020). Fibrosis in psoriasis: A new frontier in disease persistence. Experimental Dermatology, 29(5), 422–430. https://doi.org/10.1111/exd.14019

Lee, J. S., Cho, H. H., & Kim, M. J. (2021). IL-17A induces MMP-9–dependent dermal remodeling in psoriasis. Journal of Dermatological Science, 103(1), 17–25. https://doi.org/10.1016/j.jdermsci.2021.06.009

Patil, P., Desai, S., & Nayak, S. (2023). IL-17–driven angiogenic remodeling in psoriatic skin: Role of MMP-9. Vascular Pharmacology, 156, 107083. https://doi.org/10.1016/j.vph.2023.107083

Watanabe, R., Okazaki, S., & Oka, A. (2021). Single-cell mapping reveals persistent IL-17A+ populations in resolved psoriatic lesions. Journal of Clinical Investigation, 131(12), e148628. https://doi.org/10.1172/JCI148628

Herrera, J. L., Nielson, J. M., Wu, Y., & Chu, C. (2022). IL-17 gene signatures persist in resolved psoriatic skin: Implications for relapse. Journal of Allergy and Clinical Immunology, 150(4), 872–881. https://doi.org/10.1016/j.jaci.2022.02.037

Borzì, C., Tenti, S., Filippini, M., & Meliconi, R. (2023). IL-17F is associated with structural progression in psoriatic arthritis: A longitudinal cohort study. Rheumatology International, 43(1), 51–60. https://doi.org/10.1007/s00296-022-05124-4

Alfieri, D. F., Lehmann, M. F., Flauzino, T., Simão, A. N. C., & Dichi, I. (2021). IL-17F as a potential biomarker of disease severity and response to treatment in psoriatic arthritis. Clinical Rheumatology, 40(12), 4785–4791. https://doi.org/10.1007/s10067-021-05922-6

Qiao, Y., Liu, L., & Xiao, Y. (2019). Serum IL-17F level predicts psoriatic arthritis risk in psoriasis. Archives of Dermatological Research, 311(4), 301–307. https://doi.org/10.1007/s00403-019-01920-9

Navarini, A. A., Valerio, L., & Eyerich, K. (2022). Cytokine signatures of biologic response in psoriatic disease. Allergy, 77(8), 2465–2475. https://doi.org/10.1111/all.15253

Martin, A., Lim, R., & Hughes, M. (2024). Cytokine-based subtyping of psoriasis: Implications for biologic therapy. Journal of Translational Autoimmunity, 7, 100197. https://doi.org/10.1016/j.jtauto.2023.100197

Das, D., Roy, S., Singh, N., & Ghosh, S. (2022). Stratifying psoriasis phenotypes based on serum cytokine clusters: A systems biology approach. Journal of Translational Medicine, 20(1), 54. https://doi.org/10.1186/s12967-022-03209-yDubin, C., Xiang, X., Scharf, S. J., & Kaplan, D. H. (2021). IL-25 promotes innate inflammation in

Fujiwara, H., Yamaguchi, R., & Inoue, K. (2021). Molecular profiling of cytokine expression in psoriatic lesions for therapy stratification. Experimental Dermatology, 30(7), 976–984. https://doi.org/10.1111/exd.14352

Inoue, Y., Nakamura, K., & Takeuchi, M. (2023). Cytokine profiles in psoriatic subtypes: Toward personalized treatment. Clinical and Experimental Dermatology, 48(1), 47–55. https://doi.org/10.1111/ced.15388